Status:
COMPLETED
Mindfulness-Based ADHD Treatment for Children: a Feasibility Study
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
7-13 years
Phase:
EARLY_PHASE1
Brief Summary
Attention-Deficit/Hyperactivity Disorder (ADHD) affects 11% of children and leads to adverse outcomes. Medications, while often effective in reducing certain ADHD symptoms, have many disadvantages, in...
Detailed Description
Attention-Deficit/Hyperactivity Disorder (ADHD) affects 11% of American children. ADHD is a source of considerable psychosocial, educational, and neurocognitive impairment. It is co-morbid with multip...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- child of any sex/gender ages 7-13;
- fulfills the Diagnostic Statistical Manual -5 criteria for ADHD (inattentive, hyperactive, or combined);
- speaks English;
- understands the assent form and provides informed assent;
- has parents who understand the consent form and provide informed consent;
- can commit to the full length of the protocol;
- is willing to undergo a wash-out period if already on ADHD medications;
- is willing to be randomized to treatment condition.
- Exclusion criteria include:
- physical conditions that may preclude participation;
- any conditions contraindicated for ADHD medications, or potential participants taking monoamine-oxidase inhibitors;
- pregnancy.
Exclusion
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 29 2024
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04737512
Start Date
February 1 2021
End Date
October 29 2024
Last Update
November 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical & Affective Neuroscience Lab
New Haven, Connecticut, United States, 06510